flomoxef has been researched along with Community Acquired Infection in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, Y; Fukuma, A; Hirade, T; Horie, A; Ito, T; Katou, F; Koike, D; Nariai, A; Saito, Y; Wakuri, M | 1 |
| Cheng, J; Hou, X; Xu, Y; Xu, Z; Yang, Q; Zhang, H | 1 |
2 other study(ies) available for flomoxef and Community Acquired Infection
| Article | Year |
|---|---|
Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactamases; Cefmetazole; Cephalosporins; Child; Child, Preschool; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Escherichia; Escherichia coli Infections; Escherichia coli Proteins; Female; Genotype; Humans; Infant; Infant, Newborn; Male; O Antigens; Retrospective Studies; Urinary Tract Infections; Virulence | 2019 |
Flomoxef showed excellent in vitro activity against clinically important gram-positive and gram-negative pathogens causing community- and hospital-associated infections.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; China; Community-Acquired Infections; Cross Infection; Gram-Negative Bacteria; Gram-Positive Bacteria; Hospitals, University; Humans; Microbial Sensitivity Tests; Polymerase Chain Reaction; Sequence Analysis, DNA | 2015 |